Purple Biotech Ltd. (PPBT) shareholders approve all extraordinary meeting proposals

Rhea-AI Filing Summary

Purple Biotech Ltd. reports that shareholders approved all proposals presented at its Extraordinary General Meeting held on December 15, 2025 at the company offices in Rehovot, Israel. The proposals were described in the company proxy statement furnished on October 28, 2025 and received the requisite votes under Israeli Companies Law and the company articles of association.

The company also states that this Form 6-K, including its exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, so those offering documents now include these meeting results.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of December 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F ☒    Form 40-F ☐

Purple Biotech Ltd. (the “Company” or the “Registrant”) is announcing the results of the Extraordinary General Meeting of Shareholders of the Company held on December 15, 2025, at the Company’s offices (the “Meeting”). At the Meeting, the shareholders of the Company voted on the proposals described in the Company’s Proxy Statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange Commission on October 28, 2025 (the “Proxy Statement”).

Each of the proposals presented for approval at the Meeting was approved by the requisite vote of the Company’s shareholders in accordance with the Israeli Companies Law, 5759-1999 and the Company’s articles of association, as described in the Proxy.

Incorporation by Reference

This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107), the Registrant’s Registration Statement on Form F-3, originally filed with the Securities and Exchange Commission on December 7, 2022 (Registration file number 333-268710), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), and the Registrant’s Registration Statement on Form F-3, originally  filed with the Securities and Exchange Commission on May 17, 2023 (Registration file number 333-268710), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

December 16, 2025	PURPLE BIOTECH LTD.
	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

2

FAQ

What did Purple Biotech (PPBT) report in its December 2025 Form 6-K?

Purple Biotech reported that shareholders approved all proposals presented at its Extraordinary General Meeting held on December 15, 2025, as described in its earlier proxy statement.

When and where was Purple Biotechs Extraordinary General Meeting held?

The Extraordinary General Meeting of Purple Biotech shareholders was held on December 15, 2025 at the company offices on Oppenheimer Street in the Science Park in Rehovot, Israel.

Were all proposals at Purple Biotechs Extraordinary General Meeting approved?

Yes. The company states that each proposal presented for approval at the meeting was approved by the requisite shareholder vote in accordance with Israeli Companies Law and the company articles of association.

Where can investors find details of the proposals voted on at Purple Biotech (PPBT)?

The proposals were described in the company proxy statement for the meeting, which was furnished as an exhibit to a Form 6-K submitted on October 28, 2025.

How does this Purple Biotech meeting affect its registration statements?

The company states that this Form 6-K, including its exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, making the meeting results part of those documents.

Which SEC form did Purple Biotech use to report these shareholder vote results?

Purple Biotech reported the Extraordinary General Meeting results using a Report of Foreign Private Issuer on Form 6-K under the Securities Exchange Act of 1934.